Changeflow GovPing Pharma & Drug Safety Patent Application for Metabolism Disease Thera...
Routine Notice Added Draft

Patent Application for Metabolism Disease Therapeutic Agents

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO has published a new patent application (US20260085322A1) for therapeutic agents targeting metabolism-associated diseases, such as MAFLD. The application was filed on September 6, 2023, by inventors from the USPTO.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a publication of a patent application filed with the USPTO, specifically application number US20260085322A1. The application, filed on September 6, 2023, describes therapeutic agents and methods for treating metabolism-associated diseases, including metabolism-associated fatty liver disease (MAFLD).

As this is a patent application, it does not impose immediate regulatory obligations on entities. However, it signals potential future intellectual property and market exclusivity for novel treatments in this therapeutic area. Companies involved in the research, development, or commercialization of treatments for metabolic diseases should monitor the progress of this and similar patent applications as they may impact future market entry and competitive landscapes.

Archived snapshot

Mar 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

THERAPEUTIC AGENTS FOR METABOLISM-ASSOCIATED DISEASES

Application US20260085322A1 Kind: A1 Mar 26, 2026

Inventors

Santiago VERNIA, Helen PATERSON, Sijia YU, Michael MANOLAKAKIS, Andrew JOBBINS

Abstract

Provided herein is a target for the treatment of metabolism-associated diseases, such as metabolism-associated fatty liver disease (MAFLD). Also provided are agents for the treatment of said diseases and methods of using said agents.

CPC Classifications

C12N 15/1138 A61P 3/06 C12N 2310/11 C12N 2310/315 C12N 2310/321 C12N 2320/33

Filing Date

2023-09-06

Application No.

19109304

View original document →

Named provisions

Abstract Inventors CPC Classifications

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 6th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260085322A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development Therapeutic Agent Research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Healthcare Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!